IAG’s CEO Speaks to the Science Advisory Board. Watch her Interview!
Olga Kubassova, PhD, CEO of Image Analysis Group, spoke with ScienceBoard.net about how computational analysis is improving clinical trial imaging and impacts efficacy results for emerging therapeutics.
During the discussion, Dr. Kubassova explained the importance of pairing the proper imaging modality (x-ray, histopathology, MRI, computed tomography, ultrasound, single-photon emission computed tomography, and positron emission tomography) with the appropriate therapeutic strategy in order to effectively assess the effect of a specific drug. Especially today when clinical trials are increasingly dependent on sophisticated tools to help determine the physiological effects of various therapeutic candidates, understand the molecular underpinnings of human diseases, and decrease the number of patients needed in experimental designs.
‘In a clinical trial setting, quantitative imaging approaches can provide confirmation that the expected drug effects match the actual physiological effects. Quantitative image analysis provides confidence in drug development’, Dr. Kubassova said.
Dr. Samantha Black, Editor in Chief is also discussing with Dr. Kubassova the specifics of IAG’s cloud-based technology platform, called Dynamika, and how it helps biotech and pharma players to explore the use of quantitative imaging methodologies for oncology, rheumatology, and neurology indications.
‘As more complex therapies are being developed, the research community needs to be sure that the strategy behind efficacy assessment of these therapies is the right strategy’, Kubassova said. ‘Quantitative analysis can provide an objective way to explain clinical trial data.’
Watch the interview here: https://www.scienceboard.net/
About The Science Advisory Board
The Science Advisory Board was established in 1997. It is an expert network of scientists immersed in biological research, drug discovery, and biopharmaceutical production. The Science Advisory Board is the source for discovery and development in the life sciences. Our mission is to be a catalyst for future breakthroughs in the life sciences. We provide a channel for researchers, professionals, trainees, and advocates to keep a thumb on the pulse of life science and biopharmaceutical news and trends.
About Olga Kubassova
Dr. Olga Kubassova is a mathematician by background with MS in Mathematics from St. Petersburg State University, Russia, MS in Information Technology from Lappeenranta University of Technology, Finland and a PhD in Computer Science from the University of Leeds, UK.
Dr. Olga Kubassova is the founding scientist and CEO of IAG, Image Analysis Group, an imaging expert company. She started IAG straight after her PhD with an idea to bring the best of mathematics and computer science to optimize clinical development process while using imaging derived biomarkers to reliably and objectively assess efficacy of a novel drug.
Today IAG is a recognized partner to many blue-chip pharma companies in rheumatology, oncology and neurology. Since completing her PhD research in the area of MRI algorithm development for musculoskeletal disorders, Olga has been a significant contributor to the development of MRI as a clinical research and diagnostic tool in rheumatoid arthritis, osteoarthritis and other inflammatory joint diseases. She has co-authored over 60 articles, 7 book chapters and a number of abstracts that have built a significant evidence base for the medical imaging as a sensitive and objective biomarker for the assessment of various diseases and as an early measure of efficacy of new drugs. Olga is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative; she is an editor and reviewer of several scientific journals.
Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
About IAG, Image Analysis Group
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. https://www.ia-grp.com